25(OH)D |
25-hydroxyvitamin D |
ACE |
Angiotensin converting enzyme |
ACEi |
Angiotensin converting enzyme inhibitors |
apoCIII |
Apolipoprotein CIII |
ARB |
Angiotensin receptor blockers |
BMI |
Body mass index |
CK |
Creatin kinase |
CKD |
Chronic kidney disease |
CNI |
Calcineurin inhibitors |
CVD |
Cardiovascular disease |
CYP |
Cytochromes P |
CYP2C9 |
Cytochrome P450 family 2 subfamily C member 9 |
CYP450 |
P450 cytochrome |
DPP-4i |
Dipeptidyl peptidase-4 inhibitors |
ECM |
Extracellular matrix |
eGFR |
Estimated glomerular filtration rate |
FGF |
Fibroblast growing factors |
FGF23 |
Fibroblast growth factor23 |
GI |
Gastrointestinal |
GFR |
Glomerular filtration rate |
GLP-1 RA |
Glucagon-like peptide-1 receptor agonists |
HFrEF |
Heart failure with reduced ejection fraction |
HDL |
High-density lipoprotein |
HMG-CoA |
3-hydroxy-3-methyl-glutaryl-coenzyme A |
HTN |
Hypertension |
IST |
Immunosuppressive therapy |
KT |
Kidney transplantation |
LDL |
Low-density lipoprotein |
mTOR |
Mammalian target of rapamycin |
NRT |
Nicotine replacement therapy |
PCSK9 |
Proprotein convertase subtilisin/kexin type 9 |
PTDM |
Post-transplant diabetes mellitus |
QoL |
Quality of Life |
RAAS |
Renin-Angiotensin-Aldosterone System |
RDN |
Renal denervation |
SA |
Sleep apnea |
SGLT2i |
Sodium glucose cotransporter-2 inhibitors |
SPAK |
SPS1-related proline/alanine-rich kinase |
TRAS |
Transplant renal artery stenosis |
VLDL |
Very low-density lipoprotein |
WNK |
With-no-lysine [K] kinase |